AC
Acorn Capital Advisors, LLC
Momentum followerQuality / disciplined sizing
Total reported value
$351.8M
Reporting period: 2026-03-31 · Number of holdings: 22
ACORN CAPITAL ADVISORS, LLC disclosed 22 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $351.8M and a quarterly turnover rate of 31.1%.
Personality snowflake
- Concentration
- 56.9
- Portfolio Stability
- 31.15
- Momentum/Contrarian
- 100
- Sector conviction
- 0
- Diversification
- 44
- Sizing Uniformity
- 85.06
Recent moves
Add CGON
-0.1% $29.6M
Trim URGN
+15.5% -$3.8M
Add 430
0.0% $21.5M
Trim HELP
-2.1% -$5.5M
Trim TRVI
0.0% -$1.3M
Trim VSTM
0.0% -$3.6M
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals INC | Stock-Other | 26.17% | +2.27% | — | |
| 2 | CGON | Cg Oncology INC | Stock-Other | 21.77% | +5.85% | -0.09% | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 8.55% | -2.94% | +15.53% | |
| 4 | PBYI | Puma Biotechnology INC | Stock-Other | 7.50% | -0.83% | — | |
| 5 | TRVI | Trevi Therapeutics INC | Stock-Other | 7.27% | -1.83% | — | |
| 6 | CADL | Candel Therapeutics INC | Stock-Other | 4.89% | -0.05% | +35.55% | |
| 7 | BCAX | Bicara Therapeutics INC | Stock-Other | 3.64% | -0.03% | — | |
| 8 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 3.34% | +0.55% | — | |
| 9 | JBIO | Jade Biosciences INC | Stock-Other | 3.14% | +3.14% | NEW | |
| 10 | TARA | Protara Therapeutic INC | Stock-Other | 2.59% | -0.57% | — | |
| 11 | VSTM | Verastem INC | Stock-Other | 2.21% | -1.63% | — | |
| 12 | HELP | Cybin INC | Stock-Other | 2.10% | -2.26% | -2.08% | |
| 13 | LONA | Leonabio INC | Stock-Other | 1.85% | +0.56% | +26.47% | |
| 14 | AURA | Aura Biosciences INC | Stock-Other | 1.13% | +0.03% | — | |
| 15 | WHWK | Whitehawk Therapeutics INC | Stock-Other | 1.12% | +0.19% | — | |
| 16 | CRDF | Cardiff Oncology INC | Stock-Other | 0.81% | -1.06% | -10.19% | |
| 17 | QTTB | Q32 Bio INC | Stock-Other | 0.57% | +0.01% | -36.15% | |
| 18 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 0.46% | +0.46% | NEW | |
| 19 | JSPR | Jasper Therapeutics INC | Stock-Other | 0.35% | -0.76% | -20.99% | |
| 20 | ASNSUSD | X4 Pharmaceuticals INC | Stock-Other | 0.27% | -0.10% | -14.38% | |
| 21 | BCABGBP | Bioatla INC | Stock-Other | 0.25% | -0.68% | +11.81% | |
| 22 | VYNE | Vyne Therapeutics INC | Stock-Other | — | — | — |
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
Holding changes this quarter
Acorn Capital Advisors, LLC's most significant position changes for 2026-03-31: New buy: Jade Biosciences INC (JBIO); New buy: Karyopharm Therapeutics INC (KPTI); Sold out: Acrivon Therapeutics INC (ACRV); Trim: Cg Oncology INC (CGON) — shares -0.09%; Add: UroGen Pharma Ltd. (URGN) — shares +15.53%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology INC | +5.9% | -0.09% | Trim |
| 2 | 430 | Terns Pharmaceuticals INC | +2.3% | — | Unchanged |
| 3 | LONA | Leonabio INC | +0.6% | +26.47% | Add |
| 4 | OKUR | Onkure Therapeutics Inc-a | +0.6% | — | Unchanged |
| 5 | WHWK | Whitehawk Therapeutics INC | +0.2% | — | Unchanged |
| 6 | AURA | Aura Biosciences INC | 0% | — | Unchanged |
| 7 | QTTB | Q32 Bio INC | 0% | -36.15% | Trim |
| 8 | VYNE | Vyne Therapeutics INC | — | — | Unchanged |
| 9 | BCAX | Bicara Therapeutics INC | 0% | — | Unchanged |
| 10 | CADL | Candel Therapeutics INC | -0.1% | +35.55% | Add |
| 11 | ASNSUSD | X4 Pharmaceuticals INC | -0.1% | -14.38% | Trim |
| 12 | TARA | Protara Therapeutic INC | -0.6% | — | Unchanged |
| 13 | BCABGBP | Bioatla INC | -0.7% | +11.81% | Add |
| 14 | JSPR | Jasper Therapeutics INC | -0.8% | -20.99% | Trim |
| 15 | PBYI | Puma Biotechnology INC | -0.8% | — | Unchanged |
| 16 | CRDF | Cardiff Oncology INC | -1.1% | -10.19% | Trim |
| 17 | VSTM | Verastem INC | -1.6% | — | Unchanged |
| 18 | TRVI | Trevi Therapeutics INC | -1.8% | — | Unchanged |
| 19 | HELP | Cybin INC | -2.3% | -2.08% | Trim |
| 20 | URGN | UroGen Pharma Ltd. | -2.9% | +15.53% | Add |
| 21 | JBIO | Jade Biosciences INC | — | NEW | New buy |
| 22 | KPTI | Karyopharm Therapeutics INC | — | NEW | New buy |
| 23 | ACRV | Acrivon Therapeutics INC | — | EXIT | Sold out |
FAQ
What is Acorn Capital Advisors, LLC and what type of investor is it?
Acorn Capital Advisors, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $351.8M, spread across 22 disclosed positions.
What are Acorn Capital Advisors, LLC's largest equity positions?
Based on the latest 13F filing, Acorn Capital Advisors, LLC's top holdings by market value are:
1. Terns Pharmaceuticals INC (430) — $92.1M (26.2%)
2. Cg Oncology INC (CGON) — $76.6M (21.8%)
3. UroGen Pharma Ltd. (URGN) — $30.1M (8.6%)
4. Puma Biotechnology INC (PBYI) — $26.4M (7.5%)
5. Trevi Therapeutics INC (TRVI) — $25.6M (7.3%)
What changes did Acorn Capital Advisors, LLC make in its most recent portfolio filing?
In the latest reported quarter, Acorn Capital Advisors, LLC made 13 notable position adjustments: 2 new positions were initiated, 4 existing holdings were added to, 6 positions were partially reduced, and 1 were completely exited. The largest of these moves: New buy: Jade Biosciences INC (JBIO); New buy: Karyopharm Therapeutics INC (KPTI); Sold out: Acrivon Therapeutics INC (ACRV); Trim: Cg Oncology INC (CGON) — shares -0.09%; Add: UroGen Pharma Ltd. (URGN) — shares +15.53%
What sectors does Acorn Capital Advisors, LLC focus on?
Sector breakdown data is not yet available for Acorn Capital Advisors, LLC. Check back after the next 13F processing cycle.